Literature DB >> 27598744

Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers.

Hans H Herfarth1, Susan Jackson, Barbara G Schliebe, Christopher Martin, Anastasia Ivanova, Kristen Anton, Robert S Sandler, Millie D Long, Kim L Isaacs, Mark T Osterman, Bruce E Sands, Peter D Higgins, James D Lewis.   

Abstract

Investigator-initiated randomized clinical trials are the backbone of academic clinical research. Investigator-initiated trials (IITs) complement the large clinical studies sponsored by industry and address questions, which are usually not the main focus of a commercially directed research but have the purpose to confirm, improve, or refute clinically important questions with regard to diagnostic and therapeutic approaches in patient care. The aim of this review is to illustrate the necessary steps to start and complete an IIT in the field of inflammatory bowel diseases in the United States. The initial milestones for an investigator include structuring a protocol, planning and building of the trial infrastructure, accurately estimating the costs of the trial, and gauging the time span for recruitment. Once the trial has begun it is important to keep patient recruitment on target, monitor of the data quality, and document treatment emergent adverse events. This article provides a framework for the different phases of an IIT and outlines potential hurdles, which could hinder a successful execution.

Entities:  

Mesh:

Year:  2017        PMID: 27598744      PMCID: PMC5177501          DOI: 10.1097/MIB.0000000000000907

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  24 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 2.  Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.

Authors:  Geert D'Haens; Brian Feagan; Jean-Frédéric Colombel; William J Sandborn; Walter Reinisch; Paul Rutgeerts; Frank Carbonnel; Jean-Yves Mary; Silvio Danese; Richard N Fedorak; Steven Hanauer; Marc Lémann
Journal:  Gastroenterology       Date:  2012-09-20       Impact factor: 22.682

3.  Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives.

Authors:  Jessica E Ravikoff; Elisabeth B Cole; Joshua R Korzenik
Journal:  Inflamm Bowel Dis       Date:  2012-01-12       Impact factor: 5.325

4.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

5.  Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.

Authors:  Christina Ha; Thomas A Ullman; Corey A Siegel; Asher Kornbluth
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-15       Impact factor: 11.382

6.  Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.

Authors:  Mark T Osterman; Faten N Aberra; Raymond Cross; Steven Liakos; Robert McCabe; Ira Shafran; Douglas Wolf; Robert Hardi; Lisa Nessel; Colleen Brensinger; Erin Gilroy; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-30       Impact factor: 11.382

7.  Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.

Authors:  T Dassopoulos; M C Dubinsky; J L Bentsen; C F Martin; J A Galanko; E G Seidman; R S Sandler; S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  2013-11-17       Impact factor: 8.171

8.  Costs and benefits of the national cancer institute central institutional review board.

Authors:  Todd H Wagner; Christine Murray; Jacquelyn Goldberg; Jeanne M Adler; Jeffrey Abrams
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

9.  Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.

Authors:  Franck Carbonnel; Jean Frédéric Colombel; Jérome Filippi; Konstantinos H Katsanos; Laurent Peyrin-Biroulet; Mathieu Allez; Maria Nachury; Gottfried Novacek; Silvio Danese; Vered Abitbol; Fabrizio Bossa; Jacques Moreau; Gilles Bommelaer; Arnaud Bourreille; Mathurin Fumery; Xavier Roblin; Walter Reinisch; Yoram Bouhnik; Hedia Brixi; Philippe Seksik; Georgia Malamut; Martti Färkkilä; Baya Coulibaly; Olivier Dewit; Edouard Louis; Dominique Deplanque; Pierre Michetti; Hélène Sarter; David Laharie
Journal:  Gastroenterology       Date:  2015-11-26       Impact factor: 22.682

Review 10.  Reporting of sample size calculation in randomised controlled trials: review.

Authors:  Pierre Charles; Bruno Giraudeau; Agnes Dechartres; Gabriel Baron; Philippe Ravaud
Journal:  BMJ       Date:  2009-05-12
View more
  7 in total

1.  Development and evaluation of an EHR-based computable phenotype for identification of pediatric Crohn's disease patients in a National Pediatric Learning Health System.

Authors:  Ritu Khare; Michael D Kappelman; Charles Samson; Jennifer Pyrzanowski; Rahul A Darwar; Christopher B Forrest; Charles C Bailey; Peter Margolis; Amanda Dempsey
Journal:  Learn Health Syst       Date:  2020-08-28

2.  Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.

Authors:  Hans Herfarth; Edward L Barnes; John F Valentine; John Hanson; Peter D R Higgins; Kim L Isaacs; Susan Jackson; Mark T Osterman; Kristen Anton; Anastasia Ivanova; Millie D Long; Christopher Martin; Robert S Sandler; Bincy Abraham; Raymond K Cross; Gerald Dryden; Monika Fischer; William Harlan; Campbell Levy; Robert McCabe; Steven Polyak; Sumona Saha; Emmanuelle Williams; Vijay Yajnik; Jose Serrano; Bruce E Sands; James D Lewis
Journal:  Gastroenterology       Date:  2018-06-30       Impact factor: 22.682

3.  Trends and Characteristics of Clinical Trials Participation for Inflammatory Bowel Disease in the United States: A Report From IBD Partners.

Authors:  Cole Johnson; Edward L Barnes; Xian Zhang; Millie D Long
Journal:  Crohns Colitis 360       Date:  2020-04-15

4.  Declining Use of Corticosteroids for Crohn's Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial.

Authors:  M T Balart; L Russell; N Narula; G Bajaj; U Chauhan; K J Khan; A N Marwaha; E Ching; J Biro; S Halder; F Tse; J K Marshall; S M Collins; P Moayyedi; P Bercik; E F Verdu; G I Leontiadis; D Armstrong; M I Pinto-Sanchez
Journal:  J Can Assoc Gastroenterol       Date:  2020-11-20

5.  Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT).

Authors:  Gerta Rücker; Martin Schumacher; Anette Blümle; Katharina Wollmann; Karin Bischoff; Philipp Kapp; Szimonetta Lohner; Edris Nury; Kai Nitschke; Jasmin Zähringer
Journal:  BMC Med Res Methodol       Date:  2021-08-31       Impact factor: 4.615

6.  Panoramic quality assessment tool for investigator initiated trials.

Authors:  Wenwen Lv; Tingting Hu; Jiayuan Jiang; Tiantian Qu; Enlu Shen; Jiacheng Duan; Xin Miao; Weituo Zhang; Biyun Qian
Journal:  Front Public Health       Date:  2022-09-13

7.  Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost Management.

Authors:  Stuart McLennan; Alexandra Griessbach; Matthias Briel
Journal:  JAMA Netw Open       Date:  2021-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.